Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer

Birtle, Alison; Newby, Jacqueline C.; Harland, Stephen

doi:10.1038/sj.bjc.6602177

Cited by 17 publications

(8 citation statements)

References 20 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Platinum containing regimens such as epirubicin, carboplatin and 5-flurouracil have also shown antitumour activity in phase II studies (Birtle et al, 2004) and their activity in patients who fail docetaxel treatment is undergoing evaluation. Satraplatin (JM-216), an oral platinum compound, is currently being evaluated in a large international trial (SPARC), in combination with prednisolone as second-line treatment after docetaxel.…”

Section: Current Treatmentsmentioning

confidence: 99%

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

et al. 2006

View full text Add to dashboard Cite

Castration-resistant prostate cancer (CRPC) is now the second most common cause of male cancer-related mortality. Although docetaxel has recently been shown to extend the survival of patients with CRPC in two large randomised phase III studies, subsequent treatment options remain limited for these patients. A greater understanding of the molecular causes of castration resistance is allowing a more rational approach to the development of new drugs and many new agents are now in clinical development. Therapeutic targets include the adrenal steroid synthesis pathway, androgen receptor signalling, the epidermal growth factor receptor family, insulin growth factor-1 receptor, histone deacetylase, heat shock protein 90 and the tumour vasculature. Drugs against these targets are giving an insight into the molecular pathogenesis of this disease and promise to improve patient quality of life and survival. Finally, the recent discovery of chromosomal translocations resulting in the upregulation of one of at least 3 ETS genes (ERG, ETV1, ETV4) may lead to novel agents for the treatment of this disease.

show abstract

Section: Current Treatmentsmentioning

confidence: 99%

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Chao and colleagues 7 initially reported the use of ECF in 21 patients with metastatic CRPC, and reported a response rate of 43% including objective response in 3 of 5 patients with liver metastases. Birtle and colleagues 9 reported on 80 patients with CRPC treated with ECarbF, and although no patients had visceral metastases, objective response was observed in 6 of 7 patients. Combining these data with our report provides an objective response rate of 62% (95% CI, 32-85%) for patients with liver metas- gupta et al 14 reported on the use of ECarb plus IV bolus 5-fluorouracil in CRPC patients treated following prior progression despite docetaxel.…”

Section: Discussionmentioning

confidence: 99%

“…8 curve) 5 was substituted for cisplatin given that carboplatin has also been active in combination with epirubicin and 5-fluorouracil. 9 All patients received prednisone 5 mg by mouth twice a day, and continued on ADT. Complete clinical and toxicity reviews were conducted at the beginning of each cycle.…”

Section: Methodsmentioning

confidence: 99%

ECF chemotherapy for liver metastases due to castration-resistant prostate cancer

Gupta¹,

Potvin²,

Ernst³

et al. 2014

CUAJ

View full text Add to dashboard Cite

Introduction: Most men with metastatic castration-resistant prostate cancer (CRPC) have biochemical response to docetaxel, but the objective response rate is low. Liver metastases are uncommon with CRPC and associated with shorter survival. More active treatment might benefit these patients. Epirubicin, cisplatin and flurouracil (ECF) is a standard regimen for gastric cancer and response in CRPC liver metastases has been reported. We reviewed our experience with ECF in CRPC with the primary objective of determining its anti-tumour activity in patients with liver metastatic CRPC. Methods: Men with CRPC treated with ECF were identified from electronic databases and data were extracted from medical records. Men with tumours showing neuroendocrine features were excluded. Results: In total, we identified 14 CRPC patients treated with ECF were identified, of which 8 had liver metastases. The median age was 56 (range: 42-76) and all had multiple poor prognostic features. A median of 6 cycles of ECF were administered (range: 1-10) and toxicities were similar to previous reports. Of the 8 patients with liver metastases, 5 had partial remission. Conclusions: ECF was highly active in this small selected group of younger men with liver metastases from CRPC and multiple poor prognostic features. Despite important limitations, this is the third report of high objective response rates with ECF in CRPC. Objective response rates are low with current monotherapies. A higher probability of ORR is preferred for critical organ disease, therefore the anti-tumour activity should encourage testing of ECF in comparison to the most active current therapies.

show abstract

“…The authors concluded that "The number of dose reductions and treatment delays illustrate that this is an aggressive regime. It would, therefore, not be suitable for the majority of patients, but should be considered for the sizeable minority in whom combination chemotherapy is appropriate [18]." Doxil, the newest anthracycline, has been tried as a single agent in the treatment of metastatic prostate cancer.…”

Section: Mitoxantronementioning

confidence: 99%

“…Birtle recently examined the combination of epirubicin, carboplatin, and 5-fluorouracil in metastatic, hormone refractory, prostate cancer [18]. 93% of patients (75/80) were evaluable for toxicity.…”

Section: Mitoxantronementioning

confidence: 99%

Chemotherapy for Prostate Cancer

Dyrstad¹,

Shah²,

Rao³

2006

CPD

View full text Add to dashboard Cite

Androgen deprivation in patients with metastatic prostate cancer produces palliation of symptoms, reduction in PSA levels, and temporary regression of tumor in most patients. Following a brief period of disease regression that lasts an average of eighteen to twenty-four months, the disease becomes hormone refractory and progresses. Second line hormonal manipulation includes anti-androgen withdrawal, glucocorticoids, estrogens, aminogluthetimide, and ketoconazole. The response from these drugs is usually very short. Once these measures have been exhausted, the clinician is left with limited treatment options that include radionuclides and cytotoxic chemotherapy. It is the objective of this article to review the experience with chemotherapy in prostate cancer and then to discuss the role of radionuclide agents, emerging agents, and herbal therapies.

show abstract

Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer

Cited by 17 publications

References 20 publications

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

ECF chemotherapy for liver metastases due to castration-resistant prostate cancer

Chemotherapy for Prostate Cancer

Contact Info

Product

Resources

About